"There are three core strengths that separate Third Rock – the experience of its people, the innovation of the science it's pursuing with its portfolio companies and the firm's ability to think big to address some of the most challenging diseases and conditions. Combined, these strengths give Third Rock the capability to help develop new treatments that will have a dramatic and significant impact on patients' lives."

Charles Homcy, M.D.
Venture Partner at Third Rock Ventures

Company news & events

May 14, 2013 - Third Rock Ventures Expands and Strengthens Team

» Press Release

 

March 25, 2013 - Third Rock Ventures Raises $516 Million Fund III

» Press Release


 

Portfolio news & events

Agios Pharmaceuticals
March 6, 2014 - Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
» Press Release | Company News

 

bluebird bio
March 5, 2014 - bluebird bio Reports Fiscal Year End 2013 Financial Results
» Press Release | Company News

 

Eleven Biotherapeutics
March 4, 2014 - Eleven Biotherapeutics Reports Clinical and Regulatory Updates for EBI-005
» Press Release | Company News

 

March 4, 2014 - Eleven Biotherapeutics Appoints Paul Chaney to Its Board of Directors
» Press Release | Company News

 

Zafgen
February 28, 2014 - Zafgen Announces Support of NORD in Observing Rare Disease Day
» Press Release | Company News

 

Foundation Medicine
February 25, 2014 - Foundation Medicine Announces 2013 Fourth Quarter and Year-End Results and Recent Highlights
» Press Release | Company News

 

February 24, 2014 - Foundation Medicine and Collaborators Identify High Incidence of Genomic Alterations Linked to Targeted Therapies in Liver Cancer; Data Published in The Oncologist
» Press Release | Company News

 

Eleven Biotherapeutics
February 18, 2014- Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease
» Press Release | Company News

 

February 11, 2014 - Eleven Biotherapeutics Closes Initial Public Offering
» Press Release | Company News

 

Editas Medicine
February 7, 2014 - Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science
» Press Release | Company News

 

Eleven Biotherapeutics
February 6, 2014 - Eleven Biotherapeutics Prices Initial Public Offering
» Press Release | Company News

 

Agios Pharmaceuticals
February 3, 2014 - Agios Pharmaceuticals Exercises Option to U.S. Development and Commercialization Rights for IDH1 Program under Celgene Collaboration
» Press Release | Company News

 

Editas Medicine
January 27, 2014 - Editas Medicine Co-founder Develops Novel Approach to Increase Specificity of CRISPR/Cas9 Technology; Findings Published in Nature Biotechnology
» Press Release | Company News

 

Zafgen
January 15, 2014 - Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
» Press Release | Company News

 

Blueprint Medicines
January 7, 2014 - Blueprint Medicines Announces $25 Million Series B Financing
» Press Release | Company News

 

Kala Pharmaceuticals
January 6, 2014 - Kala Pharmaceuticals Appoints Howard B. Rosen as Chairman of the Board of Directors
» Press Release | Company News

 

January 6, 2014 - Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery
» Press Release | Company News

 

Agios Pharmaceuticals
January 6, 2014 - Agios Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
» Press Release | Company News

 

Foundation Medicine
January 6, 2014 - Foundation Medicine Extends and Expands Collaboration to Provide Molecular Information and Genomic Profiling for Clinical Oncology Programs
» Press Release | Company News

 

Foundation Medicine
January 2, 2014 - Foundation Medicine to Present at the 32nd Annual J.P. Morgan Healthcare Conference
» Press Release | Company News

 

Eleven Biotherapeutics
January 2, 2014 - Eleven Biotherapeutics Files Registration Statement for Proposed Initial Public Offering
» Press Release | Company News

 

January 2, 2014 - Eleven Biotherapeutics Adds Biotech Industry Veterans to Management Team and Board

» Press Release | Company News

 

bluebird bio
December 26, 2013 - bluebird bio Joins the NASDAQ Biotechnology Index
» Press Release | Company News

 

Agios Pharmaceuticals
December 23, 2013 -Agios Pharmaceuticals Added to NASDAQ Biotechnology Index
» Press Release | Company News

 

Igenica
December 17, 2013 - Igenica Appoints Oncology Expert and Industry Veteran Gwen A. Fyfe, M.D., to Board of Directors
» Press Release | Company News

 

Agios Pharmaceuticals
December 11, 2013 - Agios Advances Cancer Metabolism Collaboration with Celgene
» Press Release | Company News

 

Agios Pharmaceuticals
December 9, 2013 - Agios Presents Preclinical Data from Lead Programs at American Society of Hematology Annual Meeting
» Press Release | Company News

 

SAGE Therapeutics
December 9, 2013 - SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds and Novel Approach for the Treatment of Chronic Epilepsies
» Press Release | Company News

 

Foundation Medicine
December 9, 2013 - FoundationOne™ Heme Enables Identification of Genomic Alterations Not Identified By Conventional Methods Across Hematologic Malignancies
» Press Release | Company News

 

Foundation Medicine
December 7, 2013 - Foundation Medicine Launches FoundationOne™ Heme, Developed in Collaboration with Memorial Sloan-Kettering Cancer Center
» Press Release | Company News

 

Zafgen
December 4, 2013 - Zafgen Secures $45 Million in Series E Financing
» Press Release | Company News

 

bluebird bio
December 2, 2013 - bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
» Press Release | Company News

 

Editas Medicine
November 25, 2013 - Editas Medicine Created to Discover and Develop Novel Class of Genome Editing Therapeutics
» Press Release | Company News

 

SAGE Therapeutics
November 18, 2013 - SAGE's Novel Approach to Treatment of CNS Disorders to be Highlighted at Leading Industry and Scientific Conferences
» Press Release | Company News

 

bluebird bio
November 14, 2013 - bluebird bio Reports Fiscal Third Quarter 2013 Financial Results
» Press Release | Company News

 

Agios Pharmaceuticals
November 7, 2013 - Agios Pharmaceuticals to Present Preclinical Research at the 2013 American Society of Hematology Annual Meeting
» Press Release | Company News

 

November 7, 2013 - Agios Pharmaceuticals Reports Third Quarter 2013 Financial Results

» Press Release | Company News

 

Foundation Medicine
November 7, 2013 - Foundation Medicine Partners with Broad-based Coalition to Advance Revolutionary New Clinical Trial Design in Lung Cancer
» Press Release | Company News

 

MyoKardia
October 30, 2013 - MyoKardia Appoints Tassos Gianakakos to Chief Executive Officer
» Press Release | Company News

 

SAGE Therapeutics
October 30, 2013 - SAGE’s Discovery of Novel Allosteric Therapeutic Approach for a Broad Range of CNS Disorders Published in Journal of Neuroscience
» Press Release | Company News

 

Cytomx Therapeutics
October 16, 2013 - Publication in Science Translational Medicine Highlights Enhanced Therapeutic Index of CytomX Probody™ Therapeutic Compared to Traditional Antibody
» Press Release | Company News

 

TARIS Biomedical
October 16, 2013 - TARIS Biomedical® Enters Research Collaboration with AstraZeneca for Improved Bladder Cancer Treatments
» Press Release | Company News

 

SAGE Therapeutics
October 16, 2013 - SAGE Therapeutics Secures $20M Series B Financing
» Press Release | Company News

 

Edimer
October 8, 2013 - Edimer Initiates Phase 2 Trial of EDI200 in XLHED-Affected Male Newborns
» Press Release | Company News

 

Foundation Medicine
September 25, 2013 - Foundation Medicine Prices Initial Public Offering of Common Stock
» Press Release | Company News

 

Kala Pharmaceuticals
September 24, 2013 - Kala Pharmaceuticals Named One of the "Fierce 15" Leading Biotech Companies of 2013
» Press Release | Company News

 

Jounce Therapeutics
September 24, 2013 - Jounce Therapeutics Named a 2013 "Fierce 15" Biotech Company by FierceBiotech
» Press Release | Company News

 

CytomX Therapeutics
September 24, 2013 - CytomX Therapeutics Named a 2013 "Fierce 15" Biotech Company by FierceBiotech
» Press Release | Company News

 

Agios Pharmaceuticals
September 23, 2013 - Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation
» Press Release | Company News

 

Eleven Biotherapeutics
September 20, 2013 - Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients with Dry Eye Disease
» Press Release | Company News

 

Global Blood Therapeutics
September 19, 2013 - Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company’s Board of Directors
» Press Release | Company News

 

Rhythm
September 10, 2013 - Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease
» Press Release | Company News

 

Constellation Pharmaceuticals
September 10, 2013 - Constellation Pharmaceuticals Initiates Clinical Development of CPI-0610, a Novel BET Protein Bromodomain Inhibitor, in Patients with Lymphoma

» Press Release | Company News